A new study reports that Antech's Accuplex diagnostic panel shows higher sensitivity for detecting Ehrlichia than previously available testing approaches, according to a report published by Today's Veterinary Business.

The finding matters at the exam table. Ehrlichia infection, transmitted by ticks, can produce vague clinical signs in dogs — fever, lethargy, bleeding tendencies — and false-negative results delay treatment. A more sensitive assay changes the odds that a suspect case is confirmed on the first draw rather than after symptoms progress.

What does higher sensitivity change in practice?

Sensitivity measures how reliably a test identifies infected animals. When sensitivity rises, fewer infected dogs slip through as false negatives. For practitioners in tick-endemic regions, that shift affects screening decisions, follow-up planning and the confidence with which a negative result can be reported to an owner.

Accuplex is part of Antech's in-house diagnostic lineup, and the study positions it against the performance of other Ehrlichia assays used in companion-animal practice. Today's Veterinary Business, which reported the study, did not state in its headline summary the exact sensitivity figures, the sample size or the comparison assays involved.

Veterinarians weighing the evidence should therefore review the underlying publication for study design details before changing clinic protocol. The headline claim — higher sensitivity for Ehrlichia — is the concrete finding now on the record.

Why the species and the vector matter

Ehrlichia is primarily a canine concern in companion-animal medicine, though related organisms affect other species. Dogs with tick exposure history and compatible signs are the typical candidates for testing. Improved detection supports earlier doxycycline-style intervention decisions, which remain the standard veterinary response to confirmed infection.

The study carries no direct food-animal or regulatory implications; it concerns a commercial veterinary diagnostic assay rather than a drug or vaccine subject to FDA CVM or USDA approval pathways.

The competitive diagnostic context

Antech, a Mars-owned diagnostics provider, competes with IDEXX and in-house point-of-care platforms for vector-borne disease screening volume. Performance claims backed by peer-reviewed sensitivity data are a common battleground in that market, and clinics often choose panels based on turnaround, price and published accuracy.

A validated sensitivity advantage, if confirmed across broader clinical populations, could shift purchasing and screening behavior in tick-endemic markets. Clinics running annual vector-borne panels would have a concrete reason to reassess their current platform.

Practitioners should expect Antech to circulate the study through its diagnostic communications channels, and competitors may respond with comparative data of their own.